TrialThe Journal of clinical investigation2021

Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.

Hatice Hasturk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.